How does hemodynamic ultrasound improve our competitive advantage in our market?
Hemodynamic ultrasound expedites recovery times, which improves your comparative scores and market position. Your competitors – those without hemodynamic ultrasound – are using assumption-based, indirect information (urine output, blood pressure, lactate, and cardiac output) to guide decisions. But these don’t tell the real story about heart filling, function, or volume responsiveness so they have to guess, essentially, how to get the patient to respond.
With hemodynamic ultrasound, you’ll see what to do; you’ll get a direct answer. And given your trend toward older, sicker, multiple-comorbidity patients, you need direct answers. Staying with the wrong “guess” and wrong trajectory longer can be fatal.
What is the payment (reimbursement) story for hemodynamic ultrasound?
We encourage you to work directly with your medical billing team; they are the experts for your institution.
How does a hemodynamic ultrasound investment compare with other capital deployments?
Since the ClariTEE® transesophageal echo probe detaches from the system handle, one EVO 1™ system can support multiple patients simultaneously.
To calculate the return on your ImaCor investment, use the convenient investment calculator on our site.